




ACCP

AMERICAN COLLEGE OF CLINICAL PHARMACOLOGY
Advancing Clinical Care through Pharmacology®

Volume 8 Number 8 November/December 2019

CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT

Official Publication of the American College of Clinical Pharmacology



Clinical Pharmacology in Drug Development

Volume 8 Number 8 November/December 2019

Commentary

Where Can Patients Obtain Information on the Preapproval Access Pathway to Investigational Treatment in Japan? A Survey of Patient Advocacy Organizations' Websites

Haruka Nakada and Kyoko Takashima

978

Articles

Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses of ELX-02, a Potential Treatment for Genetic Disorders Caused by Nonsense Mutations, in Healthy Volunteers

Andi Leubitz, Anat Frydman-Marom, Neal Sharpe, John van Duzer, Kathleen C.M. Campbell, and Frédéric Vanhoutte

984

Pharmacokinetics of Once-Daily Extended-Release Tacrolimus Tablets Versus Twice-Daily Capsules in De Novo Liver Transplant

Derek A. DuBay, Lewis Teperman, Kimi Ueda, Andrew Silverman, William Chapman, Angel E. Alsina, Carmelina Tyler, and Daniel R. Stevens

995

A Phase I, Open-Label, Pharmacokinetic Trial to Investigate Possible Drug-Drug Interactions Between Clobazam, Stiripentol, or Valproate and Cannabidiol in Healthy Subjects

Gilmour Morrison, Julie Crockett, Graham Blakey, and Kenneth Sommerville

1009

A Phase I Study of Intravenous Plazomicin in Healthy Adults to Assess Potential Effects on the QT/QTc Interval, Safety, and Pharmacokinetics

Jonathan Gall, Taylor Choi, Valerie Riddle, Scott Van Wart, Jacqueline A. Gibbons, and Julie Seroogy

1032

Effect of Food on the Pharmacokinetics of 2 Formulations of DRL-17822, a Novel Selective Cholestryl Ester Transfer Protein (CETP) Inhibitor, in Healthy Males

Annelieke C. Kruithof, Rajinder Kumar, Jasper Stevens, Marieke L. de Kam, Anirudh Gautam, Shanavas Alikunju, Bijay K. Padhi, Swati Kulkarni, Rajeev S. Raghuvanshi, Rajesh Gandhi, Jacobus Burggraaf, and Ingrid M.C. Kamerling

1042

Elagolix Pharmacokinetic Profiles in Women With Renal or Hepatic Impairment

Juki Ng, W. Rachel Duan, Thomas Marbury, Jeffrey M. Schmidt, and Cheri E. Klein

1053

A Phase 3, Randomized, Placebo-Controlled Evaluation of the Safety of Intravenous Meloxicam Following Major Surgery

Sergio D. Bergese, Timothy I. Melson, Keith A. Candiotti, Sabry S. Ayad, Randall J. Mack, Stewart W. McCallum, Wei Du, Alexis Gomez, and Jorge E. Marcet

1062

Pharmacokinetic Profile of a Generic Formulation of Sofosbuvir and Its Metabolite GS-331007 in Healthy Chinese Subjects

Zhenwei Shen, Xiaoxue Zhu, Hong Zhang, Hong Chen, Junqi Niu, Guiling Chen, Xiaoqiao Li, and Yanhua Ding

1073

Evaluation of the Safety, Tolerability, Pharmacokinetics, and Food Effect of Danirixin Hydrobromide Tablets in Japanese Healthy Elderly Participants

Takayuki Iida, Yuki Matsuzawa, Hirofumi Ogura, Takashi Nagakubo, Akira Wakamatsu, Claire Ambery, Bruce E. Miller, Aili L. Lazaar, and Yotaro Numachi



1081

First-in-Human Pharmacokinetics and Safety Study of GSK3008356, a Selective DGAT1 Inhibitor, in Healthy Volunteers

Malek Okour, Angela Gress, Xinyi Zhu, David Rieman, Jason D. Lickliter, and Richard A. Brigandt

1088

CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT

**Editor-in-Chief:**

David J. Greenblatt, *Tufts University, USA*

Managing Editor:

Elizabeth Marshall, *Towson, MD*

Editorial Board:

Joseph S. Bertino, Jr. *Schenectady, NY; Bertino Consulting*

Lawrence J. Botticelli, *Cambridge, MA; Lipidion Therapeutics LLC*

Michael H. Court, *Pullman, WA; Washington State University*

Hartmut Derendorf, *Gainesville, FL; University of Florida College of Pharmacy*

Michael J. Fossler, *Chesterbrook, PA; Trevena, Inc.*

Kenneth I. Kaitin, *Boston, MA; Tufts University School of Medicine*

Donald E. Mager, *Buffalo, NY; University of Buffalo*

John S. Markowitz, *Gainesville, FL; University of Florida*

Gerd Mikus, *Heidelberg, Germany; University of Heidelberg*

Diane R. Mould, *Phoenixville, PA; Projections Research Inc.*

Amin Rostami-Hodjegan, *Manchester, United Kingdom; University of Manchester*
Edward M. Sellers, *Toronto, Ontario, Canada; University of Toronto and DL Global Partners, Inc.*

Daniel S. Sitar, *Winnipeg, Manitoba, Canada; University of Manitoba*

Phil Skolnick, *Bethesda, MD; National Institute on Drug Abuse*

Karthik Venkatakrishnan, *Cambridge, MA; Takeda Pharmaceuticals International Co.*

Lisa L. von Moltke, *Waltham, MA; Alkermes, Inc.*

Darrell R. Abernethy (*Food and Drug Administration*), *founding Editorial Board member, passed away in November 2017.*

David A. Flockhart (*University of Indiana School of Medicine*), *founding Editorial Board member, passed away in November 2015.*

Aims and Scope: *Clinical Pharmacology in Drug Development* is an international, peer-reviewed journal focused on publishing high-quality clinical pharmacology studies which are primarily (but not exclusively) performed in healthy volunteers during the early phases of drug development, or after marketing approval. Acceptance of a manuscript in CPDD will be determined by scientific rigor and technical soundness rather than perceived importance of the presented results. As such, negative study results are explicitly not an obstacle for positive acceptance decisions. In addition to publication of original research articles, CPDD encourages submission (with or without invitation) of Editorials, Commentaries, and Reviews. Established in 2012 and indexed in PubMed, CPDD now publishes 8 issues per year, and will increase to monthly publication beginning in 2021. CPDD has an international Editorial Board representing the academic, industrial, and regulatory sectors of the scientific community.

Abstracting and Indexing: This journal is indexed by CAS: Chemical Abstracts Service (ACS), Embase (Elsevier), MEDLINE/PubMed (NLM), Science Citation Index Expanded (Clarivate Analytics), SCOPUS (Elsevier), Web of Science (Clarivate Analytics).

CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, (Online ISSN: 2160-7648) is published 8 times a year.

Disclaimer: The Publisher, the American College of Clinical Pharmacology and Editors cannot be held responsible for errors or any consequences arising from the use of information contained in this journal; the views and opinions expressed do not necessarily reflect those of the Publisher, the American College of Clinical Pharmacology and Editors, neither does the publication of advertisements constitute any endorsement by the Publisher, the American College of Clinical Pharmacology and Editors of the products advertised.

Copyright and Photocopying: Copyright© 2019, American College of Clinical Pharmacology. All rights reserved. No part of this publication may be reproduced, stored or transmitted in any form or by any means without the prior permission in writing from the copyright holder. Authorization to copy items for internal and personal use is granted by the copyright holder for libraries and other users registered with their local Reproduction Rights Organization (RRO), e.g., Copyright Clearance Center (CCC), 222 Rosewood Drive, Danvers, MA 01923, USA (www.copyright.com), provided the appropriate fee is paid directly to the RRO. This consent does not extend to other kinds of copying such as copying for general distribution, for advertising or promotional purposes, for creating new collective works or for resale. Special requests should be addressed to: permissions@wiley.com

Publisher: Clinical Pharmacology in Drug Development is published by Wiley Periodicals, Inc., 350 Main Street, Malden, MA 02148; Telephone: 781 388 8200; Fax: 781 388 8210; cpdd@wiley.com.

Journal Customer Services: For ordering information, claims and any enquiry concerning your journal subscription please go to www.wileycustomerhelp.com/ask or contact your nearest office.

Americas: Email: cs-journals@wiley.com; Tel: +1 781 388 8598 or +1 800 835 6770 (toll free in the USA & Canada).

Europe, Middle East and Africa: Email: cs-journals@wiley.com; Tel: +44 (0) 1865 778315.

Asia Pacific: Email: cs-journals@wiley.com; Tel: +65 6511 8000.

Japan: For Japanese speaking support, Email: cs-japan@wiley.com

Visit our Online Customer Help available in 7 languages at <https://hub.wiley.com/community/support/onlinelibrary>

Production Editor: Preetirupa Saikia (CPDD@wiley.com)

Clinical Pharmacology in Drug Development accepts articles for Open Access publication. Please visit <https://authorservices.wiley.com/author-resources/Journal-Authors/open-access/onlineopen.html> for further information about OnlineOpen.

For submission instructions, subscription and all other information visit: wileyonlinelibrary.com/journal/cpdd

Access to this journal is available free online within institutions in the developing world through the AGORA initiative with the FAO, the HINARI initiative with the WHO, and the OARE initiative with UNEP. For information visit www.aginetwork.org, www.healthinternetwork.org, and www.oaresciences.org.

Wiley's Corporate Citizenship initiative seeks to address the environmental, social, economic, and ethical challenges faced in our business and which are important to our diverse stakeholder groups. Since launching the initiative, we have focused on sharing our content with those in need, enhancing community philanthropy, reducing our carbon impact, creating global guidelines and best practices for paper use, establishing a vendor code of ethics, and engaging our colleagues and other stakeholders in our efforts. Follow our progress at www.wiley.com/go/citizenship